# US 2008/0187904 A1 · Metal chelate-labelled pepetides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187904 A1
- Document ID: US20080187904A1
- Status: Published application
- Kind: A1
- Application number: 12/026,740
- Filed: 2008-02-06
- Published: 2008-08-07
- Earliest claimed: 1994-07-25
- Assignees: Roche Diagnostics GmbH
- Inventors: Christoph Seidel; Ursula-Henrike Wienhues; Eva Hoss
- Web page: https://patentgrep.com/patent/US20080187904A1

## CPC

- C07K 14/005: from viruses
- C07F 15/0053: {without a metal-carbon linkage}
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/533: with fluorescent label
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6878: {in epitope analysis}
- G01N 33/743: {Steroid hormones}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- Y10S 435/974: Aids related test
- Y10S 435/975: Kit
- Y10S 436/811: Test for named disease, body condition or organ function
- Y10S 436/82: Hepatitis associated antigens and antibodies
- Y10S 530/82: Proteins from microorganisms
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.

## Claims

### Claim 1

Metal chelate-labelled peptide which has a maximum length of 50 amino acids and is coupled to at least one luminescent metal chelate at least one amino side group, wherein the at least one luminescent metal chelate is present on the peptide at a predetermined position on the peptide, and wherein the peptide comprises an immunologically reactive epitope region derived from amino acid sequences of HCV.

### Claim 2 (depends on 1)

Peptide as claimed in claim 1, wherein the epitope region is selected from the group of HCV amino acid sequences consisting of:
SRRFAQALPV WARPD,
(SEQ ID NO: 11)
PQDVKFPGGG QIVGGV,
(SEQ ID NO: 12)
EEASQHLPYI EQ,
(SEQ ID NO: 13)
QKALGLIQT,
(SEQ ID NO: 14)
SRGNHVSPTH YVPESDAA,
(SEQ ID NO: 15)
PQRKNKRNTN RRPQDVKFPG GGQIVGGV,
(SEQ ID NO: 16)
and
AWYELTPAET TVRLRAYMNT PGLPV,
(SEQ ID NO: 17)
or partial sequences thereof which have a length of at least 6 amino acids.

### Claim 3 (depends on 1)

Peptide as claimed in claim 1, wherein the epitope region is selected from the group of HCV amino acid sequences consisting of:
(SEQ ID NO: 23)
KNKRNTNRR,
(SEQ ID NO: 24)
KNKRNTNRR PQDVKFPGGGQIVGGV,
(SEQ ID NO: 26)
SQHLPYI EQG-Nle-Nle-LAEQFKQQALGLLQT, KNKRNTNRR
PQDVKFPGGGQIVGGV LLPRR,
(SEQ ID NO: 27)
NPKPQKKNKRNTNRR,
(SEQ ID NO: 28)
GQIVGGVYLLPRRGPRLG,
and
(SEQ ID NO: 29)
SQHLPYIEQ.

### Claim 4 (depends on 1)

Peptide as claimed in claim 1, wherein the luminescent metal chelate is a ruthenium chelate.

### Claim 5 (depends on 1)

Peptide as claimed in claim 1, wherein the metal chelate-labelled peptides each comprise a spacer region in which the spacer region carries the at least one metal chelate label.

### Claim 6 (depends on 5)

Peptide as claimed in claim 5, wherein the spacer region is located at the amino or/and carboxy terminus of the peptide.

### Claim 7 (depends on 1)

Reagent for the immunological determination of a specific antibody, wherein it contains a metal chelate-labelled peptide which reacts with the antibody to be determined as claimed in claim 1.

### Claim 8 (depends on 7)

Reagent as claimed in claim 7, wherein
it contains
(a) the metal chelate-labelled peptide that reacts with the antibody to be determined and,
(b) a further antigen that reacts with the antibody to be determined which is bound to a solid phase or is present in a form which is capable of binding to a solid phase.

### Claim 9

A composition consisting essentially of metal chelate-labelled peptides each having a maximum length of 50 amino acids, wherein at least one luminescent metal chelate is coupled to each peptide at predetermined position(s) on the amino terminus and/or on amino side groups of the peptide, and wherein the composition is essentially free of peptides which have a luminescent metal chelate coupled at any position other than the predetermined position(s), and wherein the metal chelate-labelled peptides each comprise an immunologically reactive epitope region and the epitope region derived from amino acid sequences of HCV.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the luminescent metal chelate is a ruthenium chelate.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the metal chelate-labelled peptides each comprise a spacer region.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the predetermined position(s) on each peptide is in the spacer region.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the spacer region is located at the amino and/or carboxy terminus of each peptide.

### Claim 14 (depends on 9)

The composition of claim 9, wherein the epitope region is selected from the group consisting of SEQ ID NOs: 11-17.

### Claim 15 (depends on 9)

The composition of claim 9, wherein the epitope region is selected from the group consisting of:
(SEQ ID NO: 23)
KNKRNTNRR,
(SEQ ID NO: 24)
KNKRNTNRR PQDVKFPGGGQIVGGV,
(SEQ ID NO: 26)
SQHLPYI EQG-Nle-Nle-LAEQFKQQALGLLQT, KNKRNTNRR
PQDVKFPGGGQIVGGV LLPRR,
(SEQ ID NO: 27)
NPKPQKKNKRNTNRR,
(SEQ ID NO: 28)
GQIVGGVYLLPRRGPRLG,
and
(SEQ ID NO: 29)
SQHLPYIEQ.

### Claim 16 (depends on 9)

A reagent for the immunological determination of a specific antibody, comprising the composition of claim 9, wherein the metal chelate-labelled peptides are reactive with the antibody to be determined.

### Claim 17 (depends on 16)

The reagent of claim 16, further comprising a further antigen which is reactive with the antibody to be determined, wherein the further antigen is bound to a solid phase or is present in a form which is capable of binding to a solid phase.

### Claim 18

A metal-chelate labelled peptide which has a maximum length of 50 amino acids and is coupled to at least one luminescent metal chelate at the amino terminus and/or amino side groups, wherein the at least one luminescent metal chelate is present at predetermined position(s) on the peptide, and wherein the peptide comprises an immunologically reactive epitope region derived from amino acid sequences of HCV and the metal-chelate labelled peptide is prepared by one of the following processes:
(1) synthesizing the peptide on a solid phase by attaching together a plurality of amino acids and/or amino acid derivatives;
providing protecting groups on any amino side groups of the amino acids and/or amino acid derivatives to which coupling with the at least one luminescent metal chelate is to be avoided so that coupling of the at least one luminescent metal chelate in the following step may only proceed at the amino terminus of the peptide; and
coupling the at least one luminescent metal chelate to the amino terminus, or
(2) synthesizing the peptide on a solid phase by attaching together a plurality of amino acids and/or amino acid derivatives which are coupled to a luminescent metal chelate, wherein the amino acid derivatives are introduced at the predetermined position(s) on the peptide.

### Claim 19 (depends on 18)

The peptide of claim 18, wherein the luminescent metal chelate is a ruthenium chelate.

### Claim 20 (depends on 18)

The peptide of claim 18, wherein the metal chelate-labelled peptides each comprise a spacer region.

### Claim 21 (depends on 20)

The peptide of claim 20, wherein the predetermined position(s) is in the spacer region.

### Claim 22 (depends on 20)

The peptide of claim 20, wherein the spacer region is located at the amino and/or carboxy terminus of the peptide.

### Claim 23 (depends on 18)

The peptide of claim 18, wherein the epitope region is selected from the group consisting of SEQ ID NOs: 11-17.

### Claim 24 (depends on 18)

The peptide of claim 18, wherein the epitope region is selected from the group consisting of:
(SEQ ID NO: 23)
KNKRNTNRR,
(SEQ ID NO: 24)
KNKRNTNRR PQDVKFPGGGQIVGGV,
(SEQ ID NO: 26)
SQHLPYI EQG-Nle-Nle-LAEQFKQQALGLLQT, KNKRNTNRR
PQDVKFPGGGQIVGGV LLPRR,
(SEQ ID NO: 27)
NPKPQKKNKRNTNRR,
(SEQ ID NO: 28)
GQIVGGVYLLPRRGPRLG,
and
(SEQ ID NO: 29)
SQHLPYIEQ.

### Claim 25 (depends on 18)

A reagent for the immunological determination of a specific antibody, comprising the peptide of claim 18, wherein the peptide is reactive with the antibody to be determined.

### Claim 26 (depends on 25)

The reagent of claim 25, further comprising a further antigen which is reactive with the antibody to be determined, wherein the further antigen is bound to a solid phrase or is present in a form which is capable of binding to a solid phase.
